


RESEARCH ARTICLE

Received 30 Oct 2024 | Accepted 25 Nov 2024 | Published Online 01 Dec 2024

<https://doi.org/10.32948/ajpt.2024.11.25>

Antigenic switch potential of influenza D virus

Abdul Bari Hejran^{1,2,*}, Khaidarov Saken^{2,*}, Rahmatullah Afghan³, Parwiz Niazi⁴

Cite this article: Hejran AB, Saken K, Afghan R, Niazi P: Antigenic switch potential of influenza D virus. *Asia Pac J Pharmacother Toxicol* 2024, 4: 95-111. <https://doi.org/10.32948/ajpt.2024.11.25>

Abstract

The antigenic variability of Influenza D virus (IDV), a recently identified pathogen with significant implications for livestock and zoonotic diseases, presents unique challenges in virology, epidemiology, and public health. This review stands out by focusing explicitly on IDV's distinct antigenic shift and drift mechanisms, which are underexplored compared to other influenza viruses. Unlike previous studies that broadly address influenza evolution, this research emphasizes IDV's specific molecular and ecological traits, particularly its hemagglutinin-esterase fusion (HEF) protein, which plays a critical role in antigenic reconfiguration. The study integrates genomic sequencing, structural bioinformatics, and epidemiological surveillance to deliver a comprehensive understanding of IDV's evolutionary potential and cross-species transmission risks. This review uniquely highlights IDV's moderate propensity for antigenic switching, particularly in livestock reservoirs such as cattle and swine, which act as amplification hosts for viral dissemination. By rigorously mapping the virus's antigenic architecture, this work provides novel insights into its adaptive mechanisms and evolutionary trajectory, offering practical implications for vaccine development, immune evasion strategies, and interspecies transmission control. The methodological foundation includes an exhaustive review of peer-reviewed literature, *in silico* simulations, and phylogenetic analyses, setting this study apart as a detailed exploration of IDV's antigenic dynamics. Findings emphasize the challenges posed by IDV variability for sustainable vaccine development, necessitating regular updates to address ongoing antigenic shifts. This study significantly advances global efforts to understand and manage IDV evolution, underscoring the urgent need for enhanced surveillance in agricultural, veterinary, and public health systems. By doing so, it bridges critical knowledge gaps and informs future diagnostic, therapeutic, and preventive strategies tailored to mitigate zoonotic threats.

Key words influenza D virus, antigenic switch, hemagglutinin-esterase fusion, zoonotic potential, host immunogenicity

1. Department of Biology, Faculty of Education, Helmand University, Helmand, Afghanistan.

2. Department of Biotechnology, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan.

3. Department of Physics, Faculty of Education, Helmand University, Helmand, Afghanistan.

4. Department of Biology, Faculty of Education, Kandahar University, Kandahar, Afghanistan.

*Correspondence: Abdul Bari Hejran (Department of Biology, Faculty of Education, Helmand University, Lashkar Gah, 3901, Afghanistan; Department of Biotechnology, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan; E-mail: abdulbari.hejran94@gmail.com) and Khaidarov Saken (Department of Biotechnology, Faculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan; Email: logicalmind1984@mail.ru).

Introduction

The Orthomyxoviridae family comprises four distinct types of influenza viruses, namely influenza A, B, C, and D. Influenza A (IAV) and B (IBV) viruses are recognized for their capacity to induce respiratory illnesses in humans, often resulting in severe health complications and seasonal influenza epidemics, with IAV possessing the potential to instigate a pandemic. In contrast, Influenza D represents the sole type of influenza virus predominantly affecting cattle, with occasional spillover occurrences into other species. Since the inaugural identification of the Influenza D virus (IDV) in 2011, it was initially isolated from a pig exhibiting severe respiratory symptoms in Oklahoma, USA. Despite its widespread presence in agricultural animals such as cattle and swine, little is known regarding the implications and pathogenesis of IDV on human health [1, 2, 3, 4, 5, 6, 7, 8, 9]. In 2020, As Liu et al. [10] noted, "The virus has since been documented to circulate among cattle and swine populations globally". Influenza D virus (IDV) is classified into four primary lineages: D/OK, D/660, D/Yama_2016, and D/Yama_2019, with a potential fifth lineage, designated D/CA2019, recently identified in California, demonstrating genetic and antigenic divergence from the other four lineages. Initially classified as C/Oklahoma/1334/2011 (C/OK), this variant exhibits only 50% amino acid similarity to ICV. Nevertheless, subsequent investigations uncovered more closely related viral variants to the now-recognized D/OK variant, reinforcing the notion of a novel and distinct influenza virus type. IDV is an enveloped, segmented, single-stranded, negative-sense RNA virus. It encodes a singular glycoprotein derived from the hemagglutinin-esterase-fusion (HEF) gene, alongside seven segments that code for the polymerase essential proteins 1 (PB1) and 2 (PB2), the polymerase acidic protein (PA), the nucleoprotein (NP), the matrix proteins (M1/M2), and non-structural proteins 1 and 2 (NS1/2) [10, 11, 12, 13, 2, 14, 15, 16, 17, 18, 19, 20, 21, 22].

Furthermore, the binding characteristics of Influenza D exhibit variability across different virus clades and wildlife species. A tissue microarray system was employed to investigate the respiratory tissues of wild and domestic animals, demonstrating that IDV can adhere to the respiratory tracts of wildlife, thereby potentially promoting transmission [23, 24]. The influenza D virus is closely related to the human influenza C virus. It is suggested to be a natural reservoir in cattle, potentially contributing to the bovine respiratory disease complex. While the pathogenic potential of IDV in humans remains largely unexplored, it poses a significant risk as an emerging pathogen for individuals working with cattle. IDV exhibits a broad host range and can cross species barriers. Emerging threats from influenza A viruses (IAVs) arise from genetic drift and shift, resulting in frequent epidemics and the necessity for annual vaccine reformulations. Pigs, quails, and bats serve as mixing vessels for IAVs, as they co-express both SA α 2,3-Gal and SA α 2,6-Gal receptors, which are essential for binding to avian and human IAVs [25, 26, 27, 28, 29, 30, 31].

Finally, the influenza D virus has been increasingly detected in cattle and swine populations across the globe, demonstrating exceptional thermal and acid stability along with a broad host range. Cattle have been identified as the natural reservoir and amplification host for IDV, with infections contributing to mild or moderate respiratory illnesses in cattle and playing a significant role in the bovine respiratory disease (BRD) complex. This complex is the most common and economically impactful cattle industry disease. Recent advances in understanding the biology and epidemiology of IDV have highlighted its pathogenesis and potential zoonotic risks. Antibodies specific to IDV have been found in several species beyond cattle and swine, including horses, small ruminants, feral swine, buffalo, camels, and humans,

particularly among those exposed to cattle. These findings underline the increasing significance of IDV as a pathogen with potential interspecies transmission. These considerations will further elaborate on various critical aspects of influenza viruses, such as the antigenic shift across all types, the agricultural theory behind IDV, and vaccination and epidemiological studies. The role of swine as intermediate vectors, along with treatment, prevention strategies, vaccine development, and prospects, will also be discussed, offering a broad and diverse range of insights into these pressing issues **Table 1** [32, 33, 26, 3, 4, 24, 34, 35, 36, 37, 38, 6, 39, 40].

Results and discussion

A research investigation in North America revealed that wild white-tailed deer (WTD) had been exposed to the influenza D virus (IDVs), suggesting the possibility of infecting various hosts, including wild animal populations. The study analyzed 264 serum samples from WTD and utilized hemagglutination inhibition assays against two co-circulating viruses. In 2020, Guan et al. [56] noted, "Exposure of white-tailed deer in North America to influenza D virus" was evident, with seropositive samples for IDV identified among both juvenile and adult deer, encompassing individuals of both sexes. A novel in vitro system utilizing caprine airway epithelial cell (AEC) cultures has been established to investigate caprine respiratory viruses and bacteria. As in 2021, Strässle et al. [57] highlight that this system involves "the establishment of caprine airway epithelial cells grown in an air-liquid interface system to study caprine respiratory viruses and bacteria". This platform has been validated through experiments involving Influenza D Virus infection and colonization by *Mycoplasma mycoides* subsp. Capri, indicating its promising applications in animal welfare research [57, 58]. A study investigating the synergistic interplay between influenza D virus (IDV) and *Mycoplasma bovis* respiratory infections in cattle revealed that initial IDV infection facilitates *M. bovis* superinfection by enhancing bacterial replication and inducing pulmonary damage. Furthermore, IDV was shown to compromise the innate immune response by reducing pro-inflammatory cytokines and chemokines. Stimulation assays involving cytosolic helicases and Toll-like receptors indicated that the primary activation of RIG-I/MDA5 leads to a desensitization of TLR2 activation, akin to the effects of IDV infection. This non-additive response modifies the TLR2-mediated signaling cascade responsible for regulating the infection [59, 58, 60]. A research initiative has established a reverse-genetics system (RGS) for the Influenza D virus, facilitating the exploration of its infection biology. The viruses derived from the RGS closely mimic their parental counterparts, enabling in-depth investigations into replication, tropism, and pathogenesis. This plasmid-based system produces infectious viruses with replication kinetics akin to wild-type strains following cultured cells' transfection. Additionally, the minigenome replication assay has revealed mutations that influence the activity of the IDV ribonucleoprotein (RNP) complex (**Figure 1**) [61, 62, 4, 20, 15, 63, 64].

Antigenic shift of all types of influenza viruses

The neuraminidase enzyme associated with influenza. Neuraminidase, a type II membrane-anchored glycoprotein on the surface of influenza virions, is essential in ensuring adequate protection. Nonetheless, neuraminidase's limited potency and stability in existing influenza vaccines present significant obstacles to eliciting robust immune responses. Strategies such as isolating and characterizing broadly reactive monoclonal antibodies against neuraminidase have been explored to augment

Table 1. Exploring the complex effects and mitigation approaches of influenza D virus across diverse biological systems.

Target tissues	Description	Control strategies	Vaccine (year, country)	Negative/Positive parameters	Clinical phase	Mechanism of action	Future prospects	References
Respiratory Tract (e.g., lungs, trachea)	Influenza D virus primarily targets the respiratory epithelium, causing respiratory illnesses in cattle, swine, and other animals. Viral replication leads to inflammation and damage to respiratory tissues.	Biosecurity: Improved biosecurity in farms. Vaccination: Development of species-specific vaccines. Surveillance: Enhanced global livestock and intermediate vectors surveillance to monitor viral mutations.	Ongoing research (no licensed vaccines yet; vaccine trials in development globally).	Positive: Shows antigenic variation, expanding host range. Negative: Cross-species transmission poses risks for zoonotic spillover—potential for reassortment with other viruses, increasing its adaptation to new hosts.	Preclinical (animal models)	Hemagglutinin-esterase fusion protein binds to sialic acid receptors, facilitating viral entry and replication in respiratory epithelial cells. Mutations enhance receptor-binding efficiency and immune evasion.	Cross-species transmission: Future research may focus on the development of multi-species vaccines. Surveillance: Global monitoring for mutations and viral evolution that could enhance zoonotic potential and the virus's adaptability to new environments.	[41, 42, 43]
Gastrointestinal Tract	Some studies suggest that IDV may target the gastrointestinal tract, particularly in cattle, causing mild symptoms. Gastrointestinal involvement is still under investigation.	Hygiene and Sanitation: Reducing fecal-oral transmission through improved sanitation in farming environments. Antivirals: Testing potential antiviral drugs targeting viral replication.	It is in progress (various trials in cattle and swine).	Positive: Reduced pathogenicity in gastrointestinal infections. Negative: Limited understanding of the virus's replication in non-respiratory tissues may lead to underestimating transmission routes.	Experimental	Viral replication in gastrointestinal tissues may rely on similar mechanisms to respiratory replication, particularly receptor-mediated entry into epithelial cells.	Antiviral Treatments: Future antiviral therapies could target respiratory and gastrointestinal infections to mitigate disease spread. Mutagenesis Studies: Understanding how mutations influence tissue tropism could open new therapeutic avenues.	[6, 44]
Immune System (Innate and Adaptive)	Mutations in the hemagglutinin-esterase fusion protein allow the virus to evade immune responses and avoid detection by neutralizing antibodies.	Immune Modulation: Use of immunomodulatory therapies to boost innate immunity in affected animals. Adjuvant Vaccines: Development of vaccines that enhance adaptive immune responses to overcome immune evasion mechanisms.	Development stage in North America (2022 trials in cattle).	Positive: Moderate stimulation of innate immune responses in early infection. Harmful: Evasion of adaptive immune responses through antigenic variation, leading to long-term immunity and vaccine efficacy challenges.	Phase I (vaccine trials)	Mutations in viral antigenic sites allow the virus to escape neutralizing antibodies, while altered surface proteins enhance immune evasion. This allows persistent infection or rapid spread in immunologically naïve populations.	Vaccine Enhancement: Future vaccines may incorporate novel adjuvants to improve immunogenicity. Genetic Engineering: Potential for using reverse genetics to produce attenuated strains that stimulate more robust immune responses.	[45, 46]

Table 1. Exploring the complex effects and mitigation approaches of influenza D virus across diverse biological systems (continued).

Target tissues	Description	Control strategies	Vaccine (year, country)	Negative/Positive parameters	Clinical phase	Mechanism of action	Future prospects	References
Endothelial Cells	IDV may infect endothelial cells, contributing to vascular inflammation and exacerbating respiratory symptoms. Although not fully established, endothelial involvement is suspected in severe cases.	Anti-inflammatory Strategies: Investigating anti-inflammatory drugs to minimize vascular damage. Prophylactic Antiviral Use: Use broad-spectrum antivirals in herds experiencing outbreaks to limit viral spread.	There is no current vaccine. Early research into endothelial effects is ongoing.	Positive: Vascular involvement may increase understanding of severe cases. Damaging: The lack of confirmed data on endothelial cell infection limits the ability to develop targeted therapies.	Exploratory studies	Potential infection of endothelial cells could contribute to vascular inflammation, though the exact mechanism of interaction between IDV and endothelial cells remains under investigation.	Host Range Expansion: Future studies could examine the potential for IDV to affect the vascular systems of non-traditional hosts, leading to a greater understanding of severe pathogenicity in humans.	[47, 48]
Neurological System (possible)	Though rare, neurological symptoms in affected animals, such as swine, have been reported in severe cases, likely secondary to systemic infection rather than primary neural invasion.	Neurological Surveillance: Increased monitoring of neurological symptoms during outbreaks. Anti-inflammatory Drugs: Testing anti-neuroinflammatory drugs in severe cases where neurological involvement is suspected.	No vaccine addressing neurological impacts.	Positive: Limited neurological involvement in most cases. Negative: Neurological symptoms may complicate treatment and prognosis in rare instances of severe systemic infection.	Not applicable	Secondary neurological effects may arise from systemic inflammatory responses rather than direct infection of neural tissues. The mechanisms remain unclear and require further investigation.	Neurological Research: Studies into potential neurotropic characteristics could be vital for assessing IDV's pathogenicity in non-traditional hosts, including humans.	[25, 49]
Reproductive System (in swine)	Possible reproductive impacts on swine are under investigation. Although preliminary studies suggest that IDV may have mild effects on reproductive tissues.	Reproductive Health Monitoring: Regular monitoring of reproductive health in swine herds during IDV outbreaks. Preventive Measures: Research into vaccine development aimed at reducing reproductive effects.	Research is in progress (no specific vaccines address reproductive impacts).	Positive: No significant reproductive health effects have been observed so far. Negative: Limited research may underestimate the virus's potential impact on reproduction, leading to prevention and control measures gaps.	Preclinical (animal studies)	Direct reproductive system infection is unlikely; reproductive impacts may be secondary to systemic disease, similar to other influenza viruses.	Long-Term Studies: Future longitudinal studies could assess whether IDV affects reproductive health over multiple generations in livestock, particularly swine, and its possible effects on fertility and neonatal health.	[50, 48]

Table 1. Exploring the complex effects and mitigation approaches of influenza D virus across diverse biological systems (continued).

Target tissues	Description	Control strategies	Vaccine (year, country)	Negative/Positive parameters	Clinical phase	Mechanism of action	Future prospects	References
Ocular Tissue (rare cases)	IDV's effect on ocular tissues remains understudied, but there have been occasional reports of conjunctivitis and other mild ocular symptoms in infected animals, typically associated with respiratory distress.	Ocular Treatment: Use of anti-inflammatory eye drops in symptomatic animals. Ocular Surveillance: Monitoring ocular symptoms in animals during outbreaks to assess correlation with respiratory infections.	There are no current vaccines for ocular impacts (rare symptomology).	Positive: Mild and self-limiting ocular involvement. Damaging: Lack of specific treatment protocols for ocular symptoms can lead to animal discomfort during respiratory infections.	There is no particular phase for ocular involvement.	Mild ocular symptoms may arise from inflammatory responses associated with respiratory infection rather than direct ocular infection by the virus.	Ocular Involvement: Further studies could clarify whether IDV can directly infect ocular tissues or whether observed symptoms are purely secondary to systemic respiratory inflammation.	[51, 52, 53]
Cardiovascular System	Cardiovascular effects are suspected but not well-documented in IDV infections. In cases of severe respiratory distress, secondary cardiovascular symptoms may arise due to systemic inflammation.	Cardiovascular Monitoring: Enhanced monitoring of cardiovascular health during outbreaks. Anti-inflammatory Drugs: Testing of cardiovascular-targeted treatments in severe systemic infections to reduce inflammation.	No current vaccine addressing cardiovascular impacts (limited research).	Positive: Rare cardiovascular symptoms observed. Negative: In cases of severe systemic infection, cardiovascular involvement could exacerbate morbidity and complicate treatment efforts.	No clinical trials for cardiovascular effects yet.	Systemic inflammation associated with severe respiratory infections could lead to cardiovascular symptoms, although direct infection of cardiovascular tissues is unlikely based on current evidence.	Future Research: Studies into the potential secondary cardiovascular effects could improve understanding of severe cases, particularly in livestock with pre-existing cardiovascular conditions, and inform treatment strategies.	[41, 54, 55]




Figure 1. The illustration provides a comprehensive breakdown of specimens categorized by age cohort, gender, total sample size, and incidence of seropositive cases. Within the juvenile cohort, 100 male specimens were analyzed, yielding 20 seropositive results, while 100 female specimens indicated 25 seropositive cases. For the adult cohort, 32 male specimens were assessed, with 10 returning seropositive, and among the 32 female specimens, 8 were identified as seropositive.

anti-neuraminidase immune reactions. The catalytic site located within the head domain of each promoter is highly conserved and serves as a target for antiviral drug and monoclonal antibody development. Cathode ions are critical for enzymatic activity and thermal stability, while the architecture of the neuraminidase stalk domain exhibits variability. Variations in the neuraminidase globular head exposure can significantly influence viral infectivity, transmission, and immunogenicity. Furthermore, the surface of the neuraminidase protein may be extensively glycosylated, contributing to its structural integrity, functionality, specificity, thermal stability, antigenic properties, and immunogenic potential. Removing glycans from the neuraminidase apex enhances protective efficacy [65, 66, 67, 68, 69, 70, 71, 24, 72, 73].

Subsequently, the reassortment between Swine H3N2 and the 2009 Pandemic H1N1 in the United States has resulted in influenza A viruses exhibiting a variety of genetic constellations. A study conducted from 2009 to 2016 identified 44 distinct genotypes of H3N2 influenza A viruses (IAV) in swine, with the predominant genotype (32.33%) characterized by a clade IV-A hemagglutinin (HA) gene, 2002-lineage neuraminidase (NA) gene, an M-pdm09 gene, and other gene segments derived from a triple reassortant internal gene (TRIG) source. This genetic diversity poses challenges for disease management within the swine industry. It presents potential public health risks, mainly if swine-adapted viruses containing H1N1pdm09 genes exhibit an elevated propensity for human infection [74, 75, 68, 76, 77, 78, 79, 80, 48, 81, 18, 82, 83, 84, 50]. A study has identified four H3N2 canine influenza viruses (CIVs) as a potential public health concern due to their close genetic affinity with human strains. The virus was isolated from nasal swabs of dogs in China between 2018 and 2020, and phylogenetic analysis uncovered 15 distinct genotypes, with genotype 15 dominating among dogs since 2017.

Molecular characterization revealed several adaptive substitutions in mammals, including HA-G146S, HA-N188D, PB2-I292T, PB2-G590S, PB2-S714I, PB1-D154G, and NP-R293K. A novel adaptive mutation, HA-V223I, was detected in H3N2 viruses from humans and swine, indicating its potential significance in mammalian adaptation. Human H3N2 vaccines do not protect H3N2 CIVs, underscoring the necessity for vigilant surveillance and monitoring [85, 86, 76, 78, 71, 87, 88, 89, 81, 90]. Shandong Province, China, has identified 21 reassortant G4 genotype Eurasian avian-like (EA) H1N1 subtypes of swine influenza viruses (SIVs) that pose potential health risks. These viruses harbor genes from multiple lineages and possess mutation sites that may enhance mammalian fitness and pathogenicity in murine models. The study advocates for improved surveillance to evaluate the pandemic potential of these viruses. SIVs are highly contagious respiratory pathogens in pigs and can infect various animal hosts, including humans, birds, dogs, cats, horses, ferrets, minks, and seals [91, 86, 92, 79, 87, 48, 89, 84].

Antigenic Diversity Among IDVs Utilizing Immune Antisera. To investigate the antigenic variation of IDV HEF proteins, hemagglutination inhibition (HI) and viral neutralization (VN) assays were performed. These assays utilized mouse polyclonal antibodies generated against specific viral strains, including D/OK, D/660, D/Yama2016, and D/Yama2019 lineages. A recombinant virus (rCA/OK) was also tested. Results confirmed that while all antisera reacted to homologous and heterologous viral strains, reactivity to heterologous viruses exhibited reduced titers. This variation underscores potential antigenic diversity among IDV HEF lineages. Notably, homologous strains showed the highest titers, while heterologous reactions were often eight-fold lower in the HI assay and up to 16-fold lower in VN tests. This pattern highlights possible antigenic differentiation across lineages




Figure 2. The illustration meticulously delineates virus strains in relation to hemagglutination inhibition (HI) and virus neutralization (VN) titers, stratified by homologous and heterologous responses. For the D/OK strain, the HI titer under homologous conditions registers at 160, with a significant reduction to 20 in heterologous conditions, while the VN titer is elevated at 320 homologously and decreases to 40 heterologously. The D/660 strain presents homologous HI titers of 128, with heterologous titers reduced to 16; VN titers show a homologous value of 256, decreasing to 32 in heterologous conditions. The D/Yama2016 strain manifests robust HI titers of 256 in homologous conditions and 32 in heterologous, accompanied by VN titers of 512 in homologous and 64 in heterologous assays. Lastly, the D/Yama2019 strain exhibits homologous HI titers of 128, with a marked reduction to 16 under heterologous conditions, and homologous VN titers at 256, declining to 32 heterologously.

(Figure 2).

Antigenic Variation Among IDV HEFs Employing Monoclonal Antibodies. Mouse hybridomas secreting monoclonal antibodies (mAbs) against HEF antigens were produced to analyze antigenicity further. Specific mAbs were found to react either with homologous viruses or across multiple strains. These results suggested the presence of strain-specific epitopes and cross-reactive regions among IDV HEFs.

Identification of Antigenic Epitopes via Monoclonal Antibodies. Virus neutralization escape mutants were generated to map antigenic epitopes on the HEF protein. Various amino acid substitutions were identified in escape mutants, highlighting the potential regions responsible for VN activity loss. By comparing these mutants' sequences with their wild-type counterparts, specific epitopes crucial for immune recognition were pinpointed.

Mapping of Epitopes on the Hemagglutinin-Esterase Fusion Molecule. The identified amino acid changes were plotted onto the HEF structure, revealing that critical antigenic epitopes were located near the receptor-binding region or within the esterase domain.

Commonality of Hemagglutinin-Esterase Epitopes across Viral Lineages. Some mAbs recognized epitopes in the receptor-binding region that were conserved across multiple viral lineages. This observation suggests that specific epitopes, such as positions 187 and 189, are preserved and critical for cross-lineage antigenic responses **Table 2** [93, 94, 2, 14, 16, 95, 96, 97, 73, 40, 98].

Antigenic Drift and Shift in Influenza. The influenza virus undergoes antigenic evolution through two primary mechanisms: antigenic drift and antigenic shift. These processes involve changes in the virus's surface glycoproteins, specifically hemagglutinin (HA) and neuraminidase (NA), leading to the continuous need for updates in vaccine antigens to match circulating strains.

Antigenic Drift is a gradual process in which small mutations in the HA and NA proteins occur over time, resulting in minor changes to the virus. These mutations can enable the virus to evade the immune responses generated by previous infections or vaccinations, making the immune response generated by existing vaccines less effective.

Antigenic Shift. In contrast, antigenic shift involves a more significant change, typically through reassortment between different viral strains. This can lead to new virus subtypes that the human population has little to no pre-existing immunity against, potentially resulting in pandemics. The constant antigenic changes presented by both drift and shift challenge vaccine development, necessitating a system of global virus tracking and annual vaccine reformulations. The World Health Organization (WHO) is critical in monitoring these changes and selecting appropriate virus strains for inclusion in seasonal influenza vaccines [21, 99, 53, 100, 80, 101].

Epidemiology and vaccinations of influenza D virus

Influenza D virus (IDV) is a significant cause of the bovine respiratory disease complex (BRDC), the cattle industry's most common and costly ailment. A recombinant strain (rD/OK-AL) was engineered to create a candidate vaccine using mutations in the PB2 and PB1 proteins to enhance cold adaptation and high-temperature sensitivity. This strain grew effectively at 33°C but not at 37°C. In mouse models, rD/OK-AL was attenuated after intranasal inoculation, leading to high antibody levels against IDV. Post-challenge with wild-type virus, IDV was undetectable in respiratory tissues, indicating complete protection. These results suggest that rD/OK-AL could be a promising candidate for developing live attenuated vaccines to control BRDC [12, 102, 92,

Table 2. Reactivity profile of mouse antisera against various viral strains.

Antiserum	Test	Titer against OK	Titer against NE	Titer against Y16	Titer against Y19	Titer against rCA/OK
α OK	HI	5,120	1,280	1,280	640	640
	VN	12,800	6,400	3,200	1,600	1,600
α NE	HI	80	640	320	160	80
	VN	100	3,200	6,400	800	200
α Y16	HI	320	320	640	80	80
	VN	800	800	3,200	800	200
α Y19	HI	640	160	320	640	320
	VN	800	800	1,600	1,600	80

2, 26, 28, 103, 31]. The research investigates the immunogenicity and efficacy of a quadrivalent neuraminidase RNA particle vaccine, Sequivity NA, marketed under the brand name Sequivity® IAV-S NA. This vaccine uses four neuraminidase antigens representing the predominant NA clades of Influenza A virus (IAV) subtypes H1N1, H1N2, and H3N2 prevalent in swine populations across the United States. During the trials, pigs received two vaccinations at three days and three weeks of age, followed by challenges with either homologous or heterologous IAV strains. The vaccine successfully elicited a strong serum neuraminidase inhibition (NI) antibody response. It conferred protection against both homologous and heterologous IAV-S strains, as in 2023, Kitikoon et al. [104] stated: "Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection" (**Figure 3**) [104, 105, 106, 107, 66, 68, 108, 109, 48].

Moreover, Bovine Respiratory Syncytial Virus (BRSV) and Bovine Parainfluenza 3 Virus (BPIV3) are significant pathogens in bovine respiratory disease (BRD), leading to substantial morbidity and economic losses. Their intricate interaction with the host's immune system necessitates the presence of neutralizing antibodies and cell-mediated immunity. According to Makoschey and Berge (2021), combination vaccines targeting both viruses are commonly employed, and understanding their roles within the BRD complex can facilitate the development of effective vaccines [110, 67, 111, 26, 112, 113, 30, 114]. Moreover, research uncovers three newly identified triple-reassortant H1N1 swine influenza viruses from pigs in Tianjin, Northern China. In 2016, Sun et al. [90] stated that "these viruses possess a genetic composition derived from the 2009 pandemic H1N1 strain, Eurasian swine, and triple-reassortant swine lineages". The reassortment occurring in Tianjin presents a potential risk to human health, given that swine influenza, a highly contagious respiratory infection, has led to outbreaks in both the United States and China [115, 20, 67, 80]. Similarly, the Influenza D virus has emerged as a novel contributor to bovine respiratory disease (BRD), leading to notable production and economic setbacks in feedlot operations. As in 2020, Alvarez et al. [116] noted, "IDV infection is endemic in La Pampa, with 68% of the examined samples testing positive." However, the clinical significance of the virus in Argentina remains to be thoroughly investigated [116, 117]. In the same way, a novel influenza virus of genus D has been identified in pigs and cattle in the United States and France, showing a

genome similarity of 94% to 99% to its U.S. counterpart. As in 2015, Ducatez et al. [118] state, "The virus, designated C/swine/Oklahoma/1334/2011 (C/OK), replicates in ferrets, which are the preferred animal model for studying influenza in humans." [118, 116, 119, 41, 117]. In Luxembourg, the influenza D virus (IDV) is widespread among cattle farms, with antibodies identified in 80.2% of cattle samples collected in 2016. The seroprevalence of the virus rose significantly from 0% to 5.9% between 2012 and 2015 [120]. The United States revealed that 19.1% of 256 swine tested were seropositive for influenza D virus, with an overall IDV seropositivity rate of 42.7% [121]. Moreover, the Influenza D virus predominantly occurs in cattle across numerous countries, exhibiting a notably high seropositivity rate of 77.5% in the United States. The virus is associated with mild to moderate respiratory ailments. It plays a role in the bovine respiratory disease complex (BRDC), representing the most economically burdensome illness impacting the U.S. cattle industry [122, 28]. The study assessed antibody levels against influenza viruses across seven age cohorts during Poland's 2018/2019 epidemic season. The peak antibody response was observed in the 10-14 age group for the A/Singapore/INFIMH-16-0019/2016 (H3N2) and B/Phuket/3073/2013 Yamagata lineage antigens. Influenza represents a significant risk to vulnerable populations, including individuals over 65, children under two years, pregnant women, and those with chronic health conditions [123, 105, 107]. A novel strain of the Influenza D virus has been isolated from affected cattle in Japan and is linked to respiratory illnesses. The hemagglutinin-esterase-fusion (HEF) gene does not belong to any recognized phylogenetic lineages [125, 11, 14]. At the same time, *Tropheryma whipplei* pneumonia has been associated with HIV-2 infection in an individual with the virus. Dogs can transmit various pathogens to humans, including canine influenza A and prevalent human influenza viruses. Italy revealed a low prevalence of exposure to influenza D virus among adult household dogs, showing no correlation between IDV infection and clinical manifestations in dogs, as well as a lack of cross-reactivity between IDV and human influenza C virus (ICV) [50, 27, 87]. A study published in *Emerging Microbes & Infections* investigated the virulence and transmissibility of canine H3N2 influenza viruses (CIVs) isolated from dogs in South Korea between 2009 and 2013. The analysis revealed that these viruses exhibited a close genetic relationship with strains previously identified in dogs from both Korea and China. Notably, the research identified non-synonymous mutations within the canine




Figure 3. The illustration provides an overview of Influenza D virus (IDV), an enveloped, spherical virus approximately 80-120 nm in diameter, with a segmented, single-stranded, negative-sense RNA genome that encodes seven proteins. Transcription is driven by the viral RNA polymerase complex through a cap-snatching mechanism. A distinctive feature of IDV is its hemagglutinin-esterase (HE) fusion protein, which enables receptor binding, viral fusion, and degradation of the host receptor. IDV shares roughly 50% amino acid identity with human influenza C virus (ICV) and similarly utilizes 9-O-acetylated sialic acid as its receptor, though segment homology levels vary.

viruses, particularly affecting the presumed H3 antigenic sites, the neuraminidase (NA) stalk regions, and various internal genes. Furthermore, the study elucidated the genetic contributions of the NA, nucleoprotein (NP), and matrix (M) genes to the adaptability of CIVs that originated from the avian H3N2 virus [126, 106, 107, 69, 29].

Likewise, the virosomal influenza vaccine administered to pigs exhibited no significant lesions in the lung, spleen, liver, or kidney tissue samples. Nevertheless, follicular lymphoid hyperplasia was detected in 71.87% of the pigs in the G2 group, while mild histiocytic infiltration was noted in 11.11% of the pigs from the G1 group and 15.62% from the G2 group. The polyvalent influenza virosome vaccine demonstrated a commendable safety profile and non-cytotoxicity in pigs, as evidenced by the findings from the TUNEL assay and the absence of adverse reactions following vaccination. Furthermore, in (2023), Haach et al. [127] indicated that “the follicular lymphoid hyperplasia observed in the mediastinal lymph nodes of vaccinated pigs remains to be investigated” [127, 73]. A DNA vaccine, FluD-Vax, has been engineered to safeguard guinea pigs from infection by two distinct lineages of the influenza D virus (D/OK and D/660). This vaccine expresses the consensus hemagglutinin-esterase fusion protein (HEF) and has undergone testing against these lineages in guinea pigs. The vaccine elicited substantial levels of neutralizing antibodies against representatives of the influenza D virus lineages, specifically D/OK and D/660 [128, 42, 129]. The study investigates the innate immune response within the respiratory epithelium of

human, porcine, and bovine hosts during influenza virus infection to uncover potential factors influencing viral cross-species transmission [131]. Influenza C and D viruses exhibit genetic similarities and utilize 9-O-acetylated sialic acids for cellular entry. Both viruses target ciliated cells, operating independently of the host and ambient temperature. Temperature pronounced affects influenza C virus (ICV) replication in cultured environments, whereas influenza D virus demonstrates efficient replication regardless of temperature and host species [131, 132, 133, 134]. Influenza viruses, encompassing types A, B, C, and D (IAV, IBV, ICV, and IDV), impact various animal species, including humans. The non-structural protein 1 (NS1) is a multifunctional protein in all influenza types, undermining host antiviral defenses. Despite performing analogous functions, NS1 proteins from various types exhibit minimal amino acid sequence homology [135, 13]. Moreover, in contrast to that for prevention, Wild watermelon, a plant rich in phytochemicals and phytoestrogens, has emerged as a promising functional food in the fight against influenza. The plant's phytochemicals and phytoestrogens, which include polyphenols, flavonoids, and prenylated compounds, demonstrate the ability to inhibit viral growth, entry, and replication. This study emphasizes the potential of wild watermelon as a preventive and therapeutic agent against influenza, exhibiting notable antiviral efficacy. Influenza, a zoonotic disease with significant public health implications, is marked by antigenic mutations that affect transmissibility and drug resistance. While antiviral medications have been developed to target various stages of viral replication,

resistance can develop within a timeframe ranging from years to decades [136, 137]. It has seven RNA segments and one major surface glycoprotein, the hemagglutinin-esterase-fusion. The virus has been identified in several countries, including France, Italy, Luxembourg, Canada, Mexico, China, Mississippi, Japan, and Nebraska. Notably, the virus has been detected in cattle, sheep, swine, horses, and goats. However, its viral genome has been confirmed only in certain animal species, with specific antibodies detected in others. In 2022, a study conducted by Trombetta et al. [138] to evaluate the prevalence of antibodies against two IDV lineages (D/660 and D/OK) in archived serum samples from swine veterinarians in Italy collected in 2004, results indicated that cattle may come into contact with the virus either during transportation or immediately afterward [138, 139]. At the same time, there is research to assess the extent of maternally acquired passive immunity in cattle from Mississippi and its influence on the onset of infectious diseases. Among 55 ailing calves, 32.7% exhibited seropositivity for Influenza D Virus (IDV), with a geometric mean viral titer (GMT) of 172.8 (± 7215.7). These calves had been housed at the facility for an average duration of 24 days at the time of sampling and had undergone 1.9 treatments for respiratory illness. Quantitative RT-PCR analysis of respiratory swabs identified IDV in 29.1% (55 out of 189) of the sick calves and 2.4% (2 out of 82) of the healthy calves, supporting the hypothesis that IDV infection correlates with bovine respiratory disease (BRD) in dairy cattle. In 2015, Ferguson et al. [140] state, "Influenza D virus infection was observed in Mississippi beef cattle with a significant percentage showing seropositivity." The calves testing positive for IDV had been at the facility for an average of 19.4 days, implying that active infection may develop within the first week of arrival at the order-buying facility. Two healthy calves, who had only been at the facility for seven days, shared the same pen. BRD is a multifaceted, multi-pathogen disease with various contributing agents. IDV, detected in cattle displaying respiratory symptoms, could potentially be one of the multiple pathogens that compromise host immunity and exacerbate the pathogenesis of respiratory disease in cattle. Metagenomics analysis of respiratory samples from 50 dairy calves with BRD revealed contig reads for bovine adenovirus 3, bovine rhinotracheitis virus A, and IDV in 62% of the specimens. However, other respiratory pathogens might account for the elevated IDV prevalence in sick versus healthy herds. The findings indicated that 94% of neonatal cattle sampled between 2013 and 2014 acquired immunity against IDV through maternal colostrum, though this immunity appeared to wane with age. By six months, many cattle were likely vulnerable to IDV infection [140, 141].

Efficacy of Two Intranasal Vaccines in Mitigating Bovine Respiratory Disease among Neonatal Beef Calves. Bovine respiratory syncytial virus (BRSV) and bovine parainfluenza-3 virus (bPI3V) are significant contributors to bovine respiratory disease (BRD) in neonatal calves globally. Vaccination is extensively implemented to mitigate BRD, with the development of intranasal vaccines for BRSV and bPI3V aimed at circumventing the interference posed by maternally derived antibodies. Numerous experimental challenge trials have demonstrated the efficacy of these intranasal vaccines; however, their effectiveness in practical field settings, particularly among newborn beef calves, has been less frequently validated. This field trial evaluated the comparative effectiveness of a commercially launched commercial BRSV-bPI3V intranasal vaccine against a benchmark counterpart in newborn beef calves raised within a cow-calf management system. A total of 935 calves across 39 farms were randomized into two vaccination cohorts (Bovalto et al. [Vaccine A], $n = 468$; Rispoval RS + PI3 Intranasal [Vaccine B], $n = 467$) and closely monitored throughout the in-house risk period, extending up to three months post-vaccination. A non-inferiority analysis assessed

the disparity in BRD prevalence between the two vaccine groups. No statistically significant differences were identified between the vaccines concerning clinical outcomes such as morbidity, mortality, the interval between vaccination and BRD onset, and the treatments administered. Given that the upper limit of the two-sided 95% confidence interval for the difference in BRD prevalence between the treatment groups (0.8%) remained below the non-inferiority margin ($d = 5\%$), Vaccine A was deemed non-inferior [142, 122, 113].

Swine intermediate vectors

The genetic shift has given rise to new strains of influenza viruses capable of facilitating efficient human-to-human transmission, thereby contributing to multiple pandemics in history. While cattle are the primary known reservoir for the influenza D virus, other small ruminants and humans have also demonstrated susceptibility to IDV infections under various circumstances [25, 34, 35, 123]. A study examining two canine influenza viruses from Korea, isolated between 2013 and 2014, revealed a close genetic relationship to the predominant H3N2 canine influenza viruses (CIVs), which possess mutations in antigenic and host-determining regions. The investigation also identified minimal genome-wide genetic variation among the H3N2 CIVs. Influenza A virus (IAV) is highly transmissible, infecting humans, mammals, and domestic and wild avian species. Dogs are regarded as intermediate hosts due to their frequent interactions with humans and respiratory tract receptors [52, 143, 107]. In Italy, molecular and virological analyses were conducted on 845 clinical samples collected from 448 pig farms experiencing respiratory distress in the Po Valley from June 2015 to May 2016. Serological evaluations were performed on 3,698 swine serum samples, including archived sera from 2009 and newly collected samples from 2015. Genetic analysis indicated that Italian swine influenza D viruses are closely aligned with the D/swine/Oklahoma/1334/2011 cluster. 2015 IDV was identified in 27 (8.1%) of the 332 cattle herds examined for respiratory pathogens. To gain a deeper understanding of the epidemiology and significance of IDV within the Italian swine population, a series of clinical specimens, sera, and archived samples were subjected to both virological and serological investigations. The serological findings demonstrated the presence of antibodies against IDV in 364 samples across 74 herds, with 59% exhibiting antibody titers of ≥ 40 . Additionally, a serological test was conducted in 27 farms (36%) to validate the presence of IDV in the swine population [144, 117, 145, 137, 88, 34, 146, 147, 78, 148].

The H1N1pdm09 virus has been transmitted from humans to swine in Brazil, with at least 30 distinct introductions occurring between 2009 and 2011 [149]. These introductions are likely characterized by self-limited infections in swine, resulting in minimal or negligible onward transmission. Nevertheless, the virus persisted in certain instances. It continued to propagate successfully among swine, as demonstrated by the clustering of monophyletic clades that encompass three or more swine sequences isolated in Brazil over several years. The HA and NA sequences from swine collected in Brazil exhibited elongated branch lengths, indicative of substantial genetic divergence and limited sampling [149]. Moreover, the D/Yama2019 lineage-like Influenza D virus (IDV) has been detected in cattle in China. The study revealed the identification of an IDV strain with nearly complete genomic sequences within Chinese cattle herds, demonstrating genetic proximity to strains found in Japan while exhibiting significant divergence from previously reported Chinese IDV strains. This finding underscores the necessity for enhanced surveillance of D/Yama2019-like viruses to gain deeper insights into the epidemiology and diversity of IDV in China [150]. The Influenza D virus is a multi-host pathogen predominantly residing

in bovine populations. It specifically attaches to 9-O-acetylated N-acetylneuraminic acid, which confers a selective evolutionary advantage, facilitating an expanded range of potential hosts [151, 152].

Influenza C and D viruses displayed a unique respiratory tissue tropism in pathogenesis in guinea pigs. Community-acquired pneumonia (CAP) in children exhibits a severity greater than that of the influenza B virus yet comparable to CAP associated with the influenza A virus. This investigation aimed to elucidate the replication dynamics, tissue tropism, and pathogenesis of human ICV (huICV) about the swine influenza D virus (swIDV) in guinea pigs. Intranasal inoculation of both viruses did not elicit clinical symptoms; however, the infected subjects shed the virus in nasal washes. The huICV demonstrated replication in the nasal turbinates, soft palate, and trachea but not in the pulmonary tissues, whereas the swIDV was capable of replicating across all four examined tissues [153, 133, 20, 154, 63, 129, 130]. The Influenza D virus (IDV), a member of the Orthomyxoviridae family, has been identified in various regions, including North America, Europe, Asia, and Africa. In South Korea, the inaugural report regarding the detection of viral RNA and the seroprevalence of IDV was conducted in 2022. Viral RNA was analyzed using real-time RT-PCR assays on 999 nasal swabs and lung tissues from cattle and 2,391 from pigs. The seroprevalence of IDV was assessed by testing 742 cattle and 1,627 pig sera utilizing a hemagglutination inhibition (HI) assay. The positive rate for viral RNA was 1.4% in cattle, while no viral RNA was identified in pigs. The study revealed a viral RNA positivity rate of 1.4% among cattle, with seropositivity rates recorded at 54.7% for cattle and 1.4% for pigs. The geometric mean antibody titers (GMT) were 68.3 in cattle and 48.5 in pigs. This study marks the first documentation of both viral RNA and antibodies to IDV in the Republic of Korea. IDV can infect and disseminate among a broad spectrum of hosts, including domestic cattle, pigs, sheep, goats, horses, camels, poultry, and wild species such as feral pigs. Cattle are recognized as the principal reservoir for IDV, with infections linked to mild to severe respiratory clinical manifestations. The recently identified IDV is believed to primarily cause respiratory illness in cattle, with significantly lesser effects on pigs. In 2022, Korean native and non-indigenous beef cattle constituted 90% of the national cattle population, while dairy cattle accounted for merely 10%. The relatively small proportion of dairy cattle in the national herd can be attributed to the lesser significance of dairy products in the traditional Korean diet [155, 117].

Clinical Manifestations, Diagnosis, and Prospective Vaccines. Influenza D virus is transmitted via direct contact and aerosolized particles over short distances. The majority of available data regarding this disease's clinical manifestations pertain predominantly to cattle infections. Notably, the potential existence of asymptomatic carriers has also been documented in bovine and various other animal species.

1. **Cattle:** Cattle serve as the primary reservoir for IDV, with extensive serological studies confirming high seroprevalence across North America and Europe and evidence of the virus's potential contribution to BRD.

2. **Swine:** IDV circulation has been confirmed in swine populations in several countries, but seroprevalence is generally lower than in cattle, suggesting further investigation into pigs' roles in IDV ecology is warranted.

3. **Camels:** High seroprevalence of IDV has been observed in camels from Africa and Asia, indicating they may also act as significant reservoirs for the virus.

4. **Small Ruminants:** Sheep and goats exhibit lower IDV susceptibility than cattle and camels, with varying seroprevalence observed in North America and Africa.

5. **Horses:** Horses show some seroprevalence to IDV, indicating

potential interspecies transmission, although the virus does not appear to cause respiratory disease in equines.

6. **Wild Animals:** Feral swine and wild deer in North America exhibit varying seroprevalence to IDV, suggesting a possible role in the virus's ecology and transmission between domestic and wild species (**Figure 4**) [156, 39].

Serology of influenza D virus

The study explored the potential cross-reactivity between Influenza D/swine (IDV) and Influenza C/Victoria (ICV) by utilizing rabbit reference anti-sera targeting two IDV lineages: Influenza D/swine/OK/1334/2011 (D/OK) and Influenza D/bovine/660/2013 (D/660), in conjunction with a human ICV strain, Influenza C/Vic. The anti-serum specific to the D/660 strain exhibited equivalent reactivity toward both viruses, achieving a hemagglutination inhibition (HI) titre of 1,280 for each, while displaying no detectable reactivity with C/Vic. In contrast, the anti-serum produced against the D/OK strain demonstrated greater specificity for the D/OK virus, yielding an HI titre of 2,560, although it also displayed cross-reactivity with D/660, attaining a titre of 640. The anti-serum directed against C/Vic was specific to the C/Vic virus, with an HI titre of 2,560 and no observable activity against either IDV lineage. The investigation involved the analysis of 364 horse serum samples collected in 2015 from six states, along with an additional 100 samples gathered in 2016 from four states. Each sample was examined for virus-specific antibodies through the standardized hemagglutinin inhibition assay (HI) conducted in triplicate. Among the 230 individual serum samples included in the analysis, 36 tested positive for antibodies against D/OK, 28 for D/660, and 37 for C/JHB. Out of the 57 total positive samples for IDVs from the 2015 serum cohort, 23 (6.3%) exhibited positivity for both IDV lineages (D/OK and D/660), while 21 (5.8%) and 13 (3.6%) were positive solely for the D/OK or D/660 lineages, respectively. Based on the cross-reactivity data from the two IDV lineages evaluated with reference rabbit anti-serum, it was hypothesized that the 23 horses with detectable antibodies to both lineages were primarily infected by D/660 or D/660-like viruses, as the D/660 anti-sera recognized both lineages with equal efficacy in the HI assay. Additionally, it remains plausible that the samples testing positive for both IDV lineages may indicate superinfection or co-infection with D/660 and D/OK, a determination complicated by the cross-reactive properties of these viral lineages and the absence of temporal data regarding the collected samples. A separate analysis of the 2015 horse serum samples from the HI trials revealed a robust positive correlation between the antibody titres of the two IDV lineages (D/660-D/OK) and one ICV strain. However, negative correlations were identified between the ICV strain and the two IDV strains. In 2016, 100 horse serum samples were collected to assess the presence of IDV- or ICV-specific antibodies, revealing three (3%) samples positive for antibodies against D/OK, two (2%) for D/660, and eight (8%) for C/JHB. The observed discrepancies in overall seroprevalence among the samples may be attributed to the smaller sample size and the more restricted population of horses involved [157, 14, 137, 158, 34, 147, 78, 148]. In conclusion, Influenza D virus (IDV) is a pivotal component of the bovine respiratory disease (BRD) complex, having been identified in livestock throughout China. Notably, during the 2022-2023 period, live IDVs were successfully isolated from cattle, revealing a remarkably high seroprevalence of 91.4% during the winter season. Furthermore, IDV RNA was detected in 11.1% of cattle across the nation, marking the first instance of IDV serosurveillance in China. In contrast, pigs and goats exhibited exceedingly low seroprevalence rates. Additionally, the study uncovered a D/660 lineage-like IDV in Chinese cattle, a variant not previously documented in Asia. Therefore, further research




Figure 4. The illustration elucidates the natural host range of distinct influenza virus types, accentuating the principal species intrinsically susceptible to each variant, with certain overlaps manifesting among the different strains. Significantly, swine represent the exclusive species documented to harbor all four influenza virus types, whereas Influenza D virus exhibits the second most extensive host range, surpassed only by Influenza A virus.

is essential to evaluate the potential risks posed by Chinese IDVs to both animal and human health. Ultimately, IDV infections are associated with mild to moderate respiratory diseases in animals and play a significant role in the BRD complex [124].

Approaches for Controlling IDV Infections and Addressing Future Risks. Influenza viruses have caused significant mortality through annual epidemics and pandemics, prompting advancements in public health infrastructure and surveillance. Recent studies have developed effective diagnostics for the Influenza D virus (IDV), including a sensitive real-time RT-PCR assay and a multiplex assay that detects multiple respiratory pathogens. Additionally, bioaerosol surveillance has shown promise for monitoring IDV in public areas. Innovative vaccine strategies, such as a DNA vaccine targeting IDV lineages and an inactivated virus vaccine, have demonstrated protective efficacy in animal models. These vaccines resulted in significant antibody responses and reduced viral titers. While progress has been made in managing IDV infections, further research is essential to evaluate and enhance antiviral strategies to prevent future outbreaks and zoonotic transmission to humans [25, 159, 38].

Conclusions

The antigenic switch potential of the Influenza D virus represents a critical area of investigation in virology, underscoring the virus's ability to adapt and evade host immune responses. Through this review, we have elucidated the mechanisms by which Influenza D may undergo antigenic variation, primarily through genetic reassortment and mutations, akin to its closely related counterparts in the Influenza A and B virus families. This capacity for antigenic shift not only facilitates viral persistence within diverse hosts but also poses significant challenges for public health initiatives aimed at controlling outbreaks. Understanding the antigenic landscape of Influenza D is essential for predicting its evolutionary trajectory and the emergence of novel strains that may cross species barriers, potentially leading to zoonotic transmission. Moreover, the implications of antigenic variability extend to vaccine development, highlighting the necessity for continuous surveillance and the formulation of adaptive immunization strategies. As we advance our understanding of the antigenic properties of Influenza D, it becomes increasingly vital to integrate genomic surveillance with epidemiological studies to better inform preventive measures. In conclusion, the antigenic switch potential of the Influenza D virus is a multifaceted phenomenon that necessitates further exploration.

Continued research in this domain is imperative to unravel the complexities of the virus's antigenic behavior and to develop robust frameworks for the mitigation of its impact on public health. Antiviral targets often become the major therapeutic task, however the efficiency of chosen tasks could be different from the purposed aim, once was effective in inhibition viral replication, next time the antiviral potency could be decreased significantly due to antiviral drug intolerance development.

Acknowledgments

No applicable.

Ethics approval

No applicable.

Data availability

The data will be available upon request.

Funding

None.

Authors' contribution

Abdul Bari Hejran undertook the responsibilities of data collection and analysis, as well as the initial drafting of the manuscript and the meticulous review of the methodology. Khaidarov Saken spearheaded the conceptualization and design of the study, orchestrated the research activities, contributed to the drafting and revision of the manuscript, and granted approval for the final version prior to submission. Parwiz Niazi executed a comprehensive literature review, facilitated data interpretation, and contributed to the formulation of specific sections of the manuscript. Rahmatullah Afghan rendered assistance with statistical analysis, enriched the interpretation of findings, and provided critical revisions to the manuscript content. Each author played a pivotal role in ensuring the meticulousness and rigor of the study from its inception to final submission.

Competing interests

None.

References

1. Liu R, Sheng Z, Huang C, Wang D, Li F: Influenza D virus. *Curr Opin Virol* 2020, 44: 154-161.
2. Su S, Fu X, Li G, Kerlin F, Veit M: Novel Influenza D virus: Epidemiology, pathology, evolution and biological characteristics. *Virulence* 2017, 8(8): 1580-1591.
3. Wang P, Zheng M, Lau SY, Chen P, Mok BW, Liu S, Liu H, Huang X, Cremin CJ, Song W, et al: Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. *mBio* 2019, 10(5): e02180-19.
4. Zhang X, Ross TM: Anti-neuraminidase immunity in the combat against influenza. *Expert Rev Vaccines* 2024, 23(1): 474-484.
5. Kondratiuk K, Poznańska A, Szymański K, Czajkowska E, Mańkowski B, Brydak LB: Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland. *Viruses* 2024, 16(7): 1105.
6. Ferguson L, Olivier AK, Genova S, Epperson WB, Smith DR, Schneider L, Barton K, McCuan K, Webby RJ, Wan XF: Pathogenesis of Influenza D Virus in Cattle. *J Virol* 2016, 90(12): 5636-5642.
7. Jiang WM, Wang SC, Peng C, Yu JM, Zhuang QY, Hou GY, Liu S, Li JP, Chen JM: Identification of a potential novel type of influenza virus in Bovine in China. *Virus Genes* 2014, 49(3): 493-496.
8. Lutteke N, Sausy A, Black AP, Wildschutz F, Muller CP: Neutralizing antibodies against influenza A in pigs before and after the 2009 pandemic, Luxembourg. *Vet Microbiol* 2014, 169(1-2): 96-101.
9. Chiapponi C, Faccini S, De Mattia A, Baioni L, Barbieri I, Rosignoli C, Nigrelli A, Foni E: Detection of Influenza D Virus among Swine and Cattle, Italy. *Emerg Infect Dis* 2016, 22(2): 352-354.
10. Molini U, Curini V, Jacobs E, Tongo E, Berjaoui S, Hemberger MY, Puglia I, Jago M, Khaiseb S, Cattoli G, et al: First influenza D virus full-genome sequence retrieved from livestock in Namibia, Africa. *Acta Trop* 2022, 232: 106482.
11. Wang M, Veit M: Hemagglutinin-esterase-fusion (HEF) protein of influenza C virus. *Protein Cell* 2016, 7(1): 28-45.
12. Ishida H, Murakami S, Kamiki H, Matsugo H, Katayama M, Sekine W, Ohira K, Takenaka-Uema A, Horimoto T: Generation of a recombinant temperature-sensitive influenza D virus. *Sci Rep* 2023, 13(1): 3806.
13. Yu J, Huang C, Sheng Z, Wang Z, Li F, Wang D: Identification of One Critical Amino Acid Residue of the Nucleoprotein as a Determinant for In Vitro Replication Fitness of Influenza D Virus. *J Virol* 2021, 95(18): e0097121.
14. Yu J, Hika B, Liu R, Sheng Z, Hause BM, Li F, Wang D: The Hemagglutinin-Esterase Fusion Glycoprotein Is a Primary Determinant of the Exceptional Thermal and Acid Stability of Influenza D Virus. *mSphere* 2017, 2(4): e00254-17.
15. Limaye S, Lohar T, Dube H, Ramasamy S, Kale M, Kulkarni-Kale U, Kuchipudi SV: Rapid evolution leads to extensive genetic diversification of cattle flu Influenza D virus. *Commun Biol* 2024, 7(1): 1276.
16. Huang C, Yu J, Hause BM, Park JY, Sreenivasan C, Upreti T, Sheng Z, Wang D, Li F: Emergence of new phylogenetic lineage of Influenza D virus with broad antigenicity in California, United States. *Emerg Microbes Infect* 2021, 10(1): 739-742.
17. Saito T, Sakuma S, Mine J, Uchida Y, Hangalapura BN: Genetic Diversity of the Hemagglutinin Genes of Influenza A Virus in Asian Swine Populations. *Viruses* 2022, 14(4): 747.
18. Limaye S, Shelke A, Kale MM, Kulkarni-Kale U, Kuchipudi SV: IDV Typer: An Automated Tool for Lineage Typing of Influenza D Viruses Based on Return Time Distribution. *Viruses* 2024, 16(3): 373.
19. Song H, Gao GF: Evaluation of the Glycan-Binding and Esterase Activities of Hemagglutinin-Esterase-Fusion Glycoprotein from Influenza D Virus. *Methods Mol Biol* 2022, 2556: 187-203.
20. Song H, Qi J, Khedri Z, Diaz S, Yu H, Chen X, Varki A, Shi Y, Gao GF: An Open Receptor-Binding Cavity of Hemagglutinin-Esterase-Fusion Glycoprotein from Newly-Identified Influenza D Virus: Basis for Its Broad Cell Tropism. *PLoS Pathog* 2016, 12(1): e1005411.
21. Kim H, Webster RG, Webby RJ: Influenza Virus: Dealing with a Drifting and Shifting Pathogen. *Viral Immunol* 2018, 31(2): 174-183.
22. Huang ZZ, Tan J, Huang P, Li BS, Guo Q, Liang LJ: The evolutionary features and roles of single nucleotide variants and charged amino acid mutations in influenza outbreaks during NPI period. *Sci Rep* 2024, 14(1): 20418.
23. Nemanichvili N, Berends AJ, Tomris I, Barnard KN, Parrish CR, Gröne A, Rijks JM, Verheije MH, de Vries RP: Influenza D binding properties vary amongst the two major virus clades and wildlife species. *Vet Microbiol* 2022, 264: 109298.
24. Kaplan BS, Falkenberg S, Dassanayake R, Neill J, Velayudhan B, Li F, Vincent AL: Virus strain influenced the interspecies transmission of influenza D virus between calves and pigs. *Transbound Emerg Dis* 2021, 68(6): 3396-3404.
25. Asha K, Kumar B: Emerging Influenza D Virus Threat: What We

- Know so Far! *J Clin Med* 2019, 8(2): 192.
26. Nissly RH, Zaman N, Ibrahim PAS, McDaniel K, Lim L, Kiser JN, Bird I, Chothe SK, Bhushan GL, Vandegrift K, et al: Influenza C and D viral load in cattle correlates with bovine respiratory disease (BRD): Emerging role of orthomyxoviruses in the pathogenesis of BRD. *Virology* 2020, 551: 10-15.
 27. Sheng Z, Ran Z, Wang D, Hoppe AD, Simonson R, Chakravarty S, Hause BM, Li F: Genomic and evolutionary characterization of a novel influenza-C-like virus from swine. *Arch Virol* 2014, 159(2): 249-255.
 28. Upreti T, Sreenivasan CC, Thomas M, Hause B, Christopher-Hennings J, Miskimis D, Pillatzki A, Nelson E, Wang D, Li F: Prevalence and characterization of seven-segmented influenza viruses in bovine respiratory disease complex. *Virology* 2023, 587: 109859.
 29. Lee J, Wang L, Palinski R, Walsh T, He D, Li Y, Wu R, Lang Y, Sunwoo SY, Richt JA, et al: Comparison of Pathogenicity and Transmissibility of Influenza B and D Viruses in Pigs. *Viruses* 2019, 11(10): 905.
 30. Holwerda M, Laloli L, Wider M, Schönecker L, Becker J, Meylan M, Dijkman R: Establishment of a Reverse Genetic System from a Bovine Derived Influenza D Virus Isolate. *Viruses* 2021, 13(3): 502.
 31. Shi HF, Zhu YM, Yan H, Ma L, Wang XZ, Xue F: Pathogenesis of a Chinese strain of bovine adenovirus type 3 infection in albino guinea pigs. *Arch Virol* 2014, 159(12): 3211-3218.
 32. Yu J, Li F, Wang D: The first decade of research advances in influenza D virus. *J Gen Virol* 2021, 102(1): jgv001529.
 33. Rijal P, Wang BB, Tan TK, Schimanski L, Janesch P, Dong T, McCauley JW, Daniels RS, Townsend AR, Huang KA: Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans. *J Virol* 2020, 94(4): e01182-19.
 34. Oliva J, Eichenbaum A, Belin J, Gaudino M, Guillotin J, Alzieu JP, Nicolle P, Brugidou R, Gueneau E, Michel E, et al: Serological Evidence of Influenza D Virus Circulation Among Cattle and Small Ruminants in France. *Viruses* 2019, 11(6): 516.
 35. Fusade-Boyer M, Pato PS, Komlan M, Dogno K, Batawui K, Goumaro E, McKenzie P, Guinat C, Secula A, Paul M, et al: Risk Mapping of Influenza D Virus Occurrence in Ruminants and Swine in Togo Using a Spatial Multicriteria Decision Analysis Approach. *Viruses* 2020, 12(2): 128.
 36. Skelton RM, Huber VC: Comparing Influenza Virus Biology for Understanding Influenza D Virus. *Viruses* 2022, 14(5): 1036.
 37. Ruiz M, Puig A, Bassols M, Fraile L, Armengol R: Influenza D Virus: A Review and Update of Its Role in Bovine Respiratory Syndrome. *Viruses* 2022, 14(12): 2717.
 38. Abdelwhab EM, Mettenleiter TC: Zoonotic Animal Influenza Virus and Potential Mixing Vessel Hosts. *Viruses* 2023, 15(4): 980.
 39. Hanon JB, Cay B: Seroprevalence of pestivirus infections is low in Belgian small ruminant flocks and is significantly associated with the presence of cattle. *Prev Vet Med* 2021, 195: 105446.
 40. Kondratiuk K, Hallmann E, Szymański K, Łuniewska K, Poznańska A, Brydak LB: Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland. *Acta Biochim Pol* 2024, 71: 12289.
 41. Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F: Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. *mBio* 2014, 5(2): e00031-00014.
 42. Collin EA, Sheng Z, Lang Y, Ma W, Hause BM, Li F: Cocirculation of two distinct genetic and antigenic lineages of proposed influenza D virus in cattle. *J Virol* 2015, 89(2): 1036-1042.
 43. Zhang T, Yin C, Boyd DF, Quarato G, Ingram JP, Shubina M, Ragan KB, Ishizuka T, Crawford JC, Tummers B, et al: Influenza Virus Z-RNAs Induce ZBP1-Mediated Necroptosis. *Cell* 2020, 180(6): 1115-1129.e1113.
 44. Trombetta CM, Marchi S, Manini I, Kistner O, Li F, Piu P, Manenti A, Biuso F, Sreenivasan C, Druce J, et al: Influenza D Virus: Serological Evidence in the Italian Population from 2005 to 2017. *Viruses* 2019, 12(1): 30.
 45. Zhai SL, Zhang H, Chen SN, Zhou X, Lin T, Liu R, Lv DH, Wen XH, Wei WK, Wang D, et al: Influenza D Virus in Animal Species in Guangdong Province, Southern China. *Emerg Infect Dis* 2017, 23(8): 1392-1396.
 46. Carascal MB, Pavon RDN, Rivera WL: Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. *Front Immunol* 2022, 13: 878943.
 47. Zhou X, Li N, Luo Y, Liu Y, Miao F, Chen T, Zhang S, Cao P, Li X, Tian K, et al: Emergence of African Swine Fever in China, 2018. *Transbound Emerg Dis* 2018, 65(6): 1482-1484.
 48. Wang G, Dos Anjos Borges LG, Stadlbauer D, Ramos I, Bermúdez González MC, He J, Ding Y, Wei Z, Ouyang K, Huang W, et al: Characterization of swine-origin H1N1 canine influenza viruses. *Emerg Microbes Infect* 2019, 8(1): 1017-1026.
 49. Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, Kniss K, Burns E, Rowe T, Foust A, et al: Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021. *Am J Transplant* 2021, 21(10): 3481-3486.
 50. Trombetta CM, Marchi S, Marotta MG, Moreno A, Chiapponi C, Montomoli E, Lanave G, Camero M, Martella V: Detection of Influenza D Antibodies in Dogs, Apulia Region, Italy, 2016 and 2023. *Emerg Infect Dis* 2024, 30(5): 1045-1047.
 51. Trombetta CM, Marchi S, Manini I, Kistner O, Li F, Piu P, Manenti A, Biuso F, Sreenivasan C, Druce J, et al: Influenza D Virus: A Potential Threat for Humans? *Proceedings* 2020, 50(1): 36.
 52. Lee E, Kim EJ, Kim BH, Song JY, Cho IS, Shin YK: Molecular analyses of H3N2 canine influenza viruses isolated from Korea during 2013-2014. *Virus Genes* 2016, 52(2): 204-217.
 53. Yang JR, Cheng CY, Chen CY, Lin CH, Kuo CY, Huang HY, Wu FT, Yang YC, Wu CY, Liu MT, et al: A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk. *Antiviral Res* 2017, 140(1): 62-75.
 54. Mossad SB: Hey, Doc: Could the 2023-2024 cold and flu season finally be the calm after the storm? *Cleve Clin J Med* 2023, 90(12): 729-734.
 55. Zhu S, Quint J, León TM, Sun M, Li NJ, Tenforde MW, Jain S, Schechter R, Hoover C, Murray EL: Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024. *MMWR Morb Mortal Wkly Rep* 2024, 73(8): 175-179.
 56. Guan M, Jacobson O, Sarafianos G, Baroch J, Deliberto TJ, Wan XF: Exposure of white-tailed deer in North America to influenza D virus. *Virology* 2022, 573: 111-117.
 57. Strässle M, Laloli L, Gultom M, V'Kovski P, Stoffel MH, Crespo Pomar S, Chanfon Bätzner A, Ebert N, Labroussaa F, Dijkman R, et al: Establishment of caprine airway epithelial cells grown in an air-liquid interface system to study caprine respiratory viruses and bacteria. *Vet Microbiol* 2021, 257: 109067.
 58. Lion A, Secula A, Rançon C, Boulesteix O, Pinaud A, Deslis A, Hägglund S, Salem E, Cassard H, Näslund K, et al: Enhanced Pathogenesis Caused by Influenza D Virus and *Mycoplasma bovis* Coinfection in Calves: a Disease Severity Linked with Overexpression of IFN- γ as a Key Player of the Enhanced Innate Immune Response in Lungs. *Microbiol Spectr* 2021, 9(3): e0169021.
 59. Gaudino M, Lion A, Sagné E, Nagamine B, Oliva J, Terrier O, Errazuriz-Cerda E, Scribe A, Sikht FZ, Simon E, et al: The Activation of the RIG-I/MDA5 Signaling Pathway upon Influenza D Virus Infection Impairs the Pulmonary Proinflammatory Response Triggered by *Mycoplasma bovis* Superinfection. *J Virol* 2023, 97(2): e0142322.
 60. Guan M, Blackmon S, Olivier AK, Zhang X, Liu L, Woolums

- A, Crenshaw MA, Liao SF, Webby R, Epperson W, et al: Time-Dependent Proinflammatory Responses Shape Virus Interference during Coinfections of Influenza A Virus and Influenza D Virus. *Viruses* 2022, 14(2): 224.
61. Yu J, Liu R, Zhou B, Chou TW, Ghedin E, Sheng Z, Gao R, Zhai SL, Wang D, Li F: Development and Characterization of a Reverse-Genetics System for Influenza D Virus. *J Virol* 2019, 93(21): e01186-19.
 62. Ishida H, Murakami S, Kamiki H, Matsugo H, Takenaka-Uema A, Horimoto T: Establishment of a Reverse Genetics System for Influenza D Virus. *J Virol* 2020, 94(10): e01767-19.
 63. Holwerda M, Kelly J, Laloli L, Stürmer I, Portmann J, Stalder H, Dijkman R: Determining the Replication Kinetics and Cellular Tropism of Influenza D Virus on Primary Well-Differentiated Human Airway Epithelial Cells. *Viruses* 2019, 11(4): 377.
 64. Yesilbag K, Toker EB, Ates O: Recent strains of influenza D virus create a new genetic cluster for European strains. *Microb Pathog* 2022, 172: 105769.
 65. Zhang X, Outlaw C, Olivier AK, Woolums A, Epperson W, Wan XF: Pathogenesis of co-infections of influenza D virus and *Mannheimia haemolytica* in cattle. *Vet Microbiol* 2019, 231: 246-253.
 66. Walz L, Kays SK, Zimmer G, von Messling V: Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. *J Virol* 2018, 92(17): e01006-18.
 67. Dias AS, Costa É A, Rajão DS, Guedes RM, Ciacci Zanella JR, Lobato ZI: Distribution of antibodies against influenza virus in pigs from farrow-to-finish farms in Minas Gerais state, Brazil. *Influenza Other Respir Viruses* 2015, 9(3): 161-167.
 68. Kaplan BS, Anderson TK, Chang J, Santos J, Perez D, Lewis N, Vincent AL: Evolution and Antigenic Advancement of N2 Neuraminidase of Swine Influenza A Viruses Circulating in the United States following Two Separate Introductions from Human Seasonal Viruses. *J Virol* 2021, 95(20): e0063221.
 69. Liang Y: Pathogenicity and virulence of influenza. *Virulence* 2023, 14(1): 2223057.
 70. Jiang H, Peng W, Qi J, Chai Y, Song H, Bi Y, Rijal P, Wang H, Oladejo BO, Liu J, et al: Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus. *mBio* 2020, 11(5): e02315-20.
 71. Gouma S, Anderson EM, Hensley SE: Challenges of Making Effective Influenza Vaccines. *Annu Rev Virol* 2020, 7(1): 495-512.
 72. Hayakawa J, Masuko T, Takehana T, Suzuki T: Genetic and Antigenic Characterization and Retrospective Surveillance of Bovine Influenza D Viruses Identified in Hokkaido, Japan from 2018 to 2020. *Viruses* 2020, 12(8): 877.
 73. Nguyen QT, Choi YK: Targeting Antigens for Universal Influenza Vaccine Development. *Viruses* 2021, 13(6): 973.
 74. Rajão DS, Walia RR, Campbell B, Gauger PC, Janas-Martindale A, Killian ML, Vincent AL: Reassortment between Swine H3N2 and 2009 Pandemic H1N1 in the United States Resulted in Influenza A Viruses with Diverse Genetic Constellations with Variable Virulence in Pigs. *J Virol* 2017, 91(4): e01763-16.
 75. Li C, Chen H: Enhancement of influenza virus transmission by gene reassortment. *Curr Top Microbiol Immunol* 2014, 385: 185-204.
 76. Allen JD, Jang H, DiNapoli J, Kleanthous H, Ross TM: Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses. *J Virol* 2019, 93(3): e00946-18.
 77. Qiu Y, Stegalkina S, Zhang J, Boudanova E, Park A, Zhou Y, Prabakaran P, Pougatcheva S, Ustyugova IV, Vogel TU, et al: Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth. *J Virol* 2020, 94(6): e01035-19.
 78. Sanogo IN, Kouakou C, Batawui K, Djegui F, Byarugaba DK, Adjin R, Adjabi K, Wabwire-Mangen F, Erima B, Atim G, et al: Serological Surveillance of Influenza D Virus in Ruminants and Swine in West and East Africa, 2017-2020. *Viruses* 2021, 13(9): 1749.
 79. Chen Y, Trovão NS, Wang G, Zhao W, He P, Zhou H, Mo Y, Wei Z, Ouyang K, Huang W, et al: Emergence and Evolution of Novel Reassortant Influenza A Viruses in Canines in Southern China. *mBio* 2018, 9(3): e00909-18.
 80. Saegerman C, Gaudino M, Savard C, Broes A, Ariel O, Meyer G, Ducatez MF: Influenza D virus in respiratory disease in Canadian, province of Québec, cattle: Relative importance and evidence of new reassortment between different clades. *Transbound Emerg Dis* 2022, 69(3): 1227-1245.
 81. Song Y, Zhang Y, Zhang B, Chen L, Zhang M, Wang J, Jiang Y, Yang C, Jiang T: Identification, Genetic Analysis, and Pathogenicity of Classical Swine H1N1 and Human-Swine Reassortant H1N1 Influenza Viruses from Pigs in China. *Viruses* 2020, 12(1): 55.
 82. Rajão DS, Gauger PC, Anderson TK, Lewis NS, Abente EJ, Killian ML, Perez DR, Sutton TC, Zhang J, Vincent AL: Novel Reassortant Human-Like H3N2 and H3N1 Influenza A Viruses Detected in Pigs Are Virulent and Antigenically Distinct from Swine Viruses Endemic to the United States. *J Virol* 2015, 89(22): 11213-11222.
 83. Cai M, Wei Z, Hu X, Ji Y, Li S, Huang J, Jin R, Liang Q, Zhang G, Zheng Z, et al: The evolution, complexity, and diversity of swine influenza viruses in China: A hidden public health threat. *Virology* 2024, 598: 110167.
 84. Gorin S, Richard G, Hervé S, Eveno E, Blanchard Y, Jardin A, Rose N, Simon G: Characterization of Influenza D Virus Reassortant Strain in Swine from Mixed Pig and Beef Farm, France. *Emerg Infect Dis* 2024, 30(8): 1672-1676.
 85. Liu L, Wang F, Wu Y, Mi W, Zhang Y, Chen L, Wang D, Deng G, Shi J, Chen H, et al: The V223I substitution in hemagglutinin reduces the binding affinity to human-type receptors while enhancing the thermal stability of the H3N2 canine influenza virus. *Front Microbiol* 2024, 15: 1442163.
 86. Umar S, Ma MJ, Gray GC: Influenza D virus was not detected among prospectively studied swine farm in multiple provinces of China. *Influenza Other Respir Viruses* 2023, 17(11): e13223.
 87. Glebova TI, Klivleyeva NG, Saktaganov NT, Shamenova MG, Lukmanova GV, Baimukhametova AM, Baiseit SB, Ongarbayeva NS, Orynkanov KA, Ametova AV, et al: Circulation of influenza viruses in the dog population in Kazakhstan (2023-2024). *Open Vet J* 2024, 14(8): 1896-1904.
 88. Mekata H, Yamamoto M, Hamabe S, Tanaka H, Omatsu T, Mizutani T, Hause BM, Okabayashi T: Molecular epidemiological survey and phylogenetic analysis of bovine influenza D virus in Japan. *Transbound Emerg Dis* 2018, 65(2): e355-e360.
 89. Anderson BD, Yondon M, Bailey ES, Duman EK, Simmons RA, Greer AG, Gray GC: Environmental bioaerosol surveillance as an early warning system for pathogen detection in North Carolina swine farms: A pilot study. *Transbound Emerg Dis* 2021, 68(2): 361-367.
 90. Sun YF, Wang XH, Li XL, Zhang L, Li HH, Lu C, Yang CL, Feng J, Han W, Ren WK, et al: Novel triple-reassortant H1N1 swine influenza viruses in pigs in Tianjin, Northern China. *Vet Microbiol* 2016, 183: 85-91.
 91. Zhao Y, Han L, Sang H, Liu S, Yang P, Hou Y, Xiao Y: Swine Influenza Viruses Isolated from 2019 to 2022 in Shandong Province, China, Exemplify the Dominant Genotype. *Genes (Basel)* 2024, 15(7): 849.
 92. Oliva J, Mettier J, Sedano L, Delverdier M, Bourges-Abella N, Hause B, Loupias J, Pardo I, Bleuart C, Bordignon PJ, et al: Murine Model for the Study of Influenza D Virus. *J Virol* 2020, 94(4): e01662-19.
 93. Katayama M, Murakami S, Ishida H, Matsugo H, Sekine W, Ohira K, Takenaka-Uema A, Horimoto T: Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping. *J Virol*

- 2024, 98(3): e0190823.
94. Odagiri T, Ishida H, Li JY, Endo M, Kobayashi T, Kamiki H, Matsugo H, Takenaka-Uema A, Murakami S, Horimoto T: Antigenic heterogeneity among phylogenetic clusters of influenza D viruses. *J Vet Med Sci* 2018, 80(8): 1241-1244.
 95. Bonilla-Aldana DK, Jimenez-Diaz SD, Barboza JJ, Rodriguez-Morales AJ: Mapping the Spatiotemporal Distribution of Bovine Rabies in Colombia, 2005-2019. *Trop Med Infect Dis* 2022, 7(12): 406.
 96. Bolton JS, Klim H, Wellens J, Edmans M, Obolski U, Thompson CP: An Antigenic Thrift-Based Approach to Influenza Vaccine Design. *Vaccines (Basel)* 2021, 9(6): 657.
 97. Bonilla-Aldana DK, Jiménez-Díaz SD, Lozada-Riascos C, Silva-Cajaleon K, Rodríguez-Morales AJ: Mapping Bovine Tuberculosis in Colombia, 2001-2019. *Vet Sci* 2024, 11(5): 220.
 98. Souza CK, Anderson TK, Chang J, Venkatesh D, Lewis NS, Pekosz A, Shaw-Saliba K, Rothman RE, Chen KF, Vincent AL: Antigenic Distance between North American Swine and Human Seasonal H3N2 Influenza A Viruses as an Indication of Zoonotic Risk to Humans. *J Virol* 2022, 96(2): e0137421.
 99. Gao J, Couzens L, Burke DF, Wan H, Wilson P, Memoli MJ, Xu X, Harvey R, Wrammert J, Ahmed R, et al: Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies. *mBio* 2019, 10(2): e00307-19.
 100. Chen Z, Bancej C, Lee L, Champredon D: Antigenic drift and epidemiological severity of seasonal influenza in Canada. *Sci Rep* 2022, 12(1): 15625.
 101. de Vries RD, Altenburg AF, Rimmelzwaan GF: Universal influenza vaccines, science fiction or soon reality? *Expert Rev Vaccines* 2015, 14(10): 1299-1301.
 102. Jang YH, Seong BL: The Quest for a Truly Universal Influenza Vaccine. *Front Cell Infect Microbiol* 2019, 9: 344.
 103. Nuwarda RF, Alharbi AA, Kayser V: An Overview of Influenza Viruses and Vaccines. *Vaccines (Basel)* 2021, 9(9): 1032.
 104. Kitikoon P, Knetter SM, Mogler MA, Morgan CL, Hoehn A, Puttamreddy S, Strait EL, Segers R: Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection. *Vaccine* 2023, 41(47): 6941-6951.
 105. Zhang Z, Li S, Zhu X, Hou J, Zhang H, Zhao B, Tian Z: Increased genetic variation of A(H3N2) virus from influenza surveillance at the end of the 2016/2017 season for Shanghai port, China. *Sci Rep* 2022, 12(1): 17089.
 106. Cardenas M, Seibert B, Cowan B, Caceres CJ, Gay LC, Cargnin Faccin F, Perez DR, Baker AL, Anderson TK, Rajao DS: Modulation of human-to-swine influenza a virus adaptation by the neuraminidase low-affinity calcium-binding pocket. *Commun Biol* 2024, 7(1): 1230.
 107. Sun H, Blackmon S, Yang G, Waters K, Li T, Tangwangvivat R, Xu Y, Shyu D, Wen F, Cooley J, et al: Zoonotic Risk, Pathogenesis, and Transmission of Avian-Origin H3N2 Canine Influenza Virus. *J Virol* 2017, 91(21): e00637-17.
 108. Cui X, Ma J, Pang Z, Chi L, Mai C, Liu H, Liao M, Sun H: The evolution, pathogenicity and transmissibility of quadruple reassortant H1N2 swine influenza virus in China: A potential threat to public health. *Virol Sin* 2024, 39(2): 205-217.
 109. Peng X, Wu H, Xu L, Peng X, Cheng L, Jin C, Xie T, Lu X, Wu N: Molecular characterization of a novel reassortant H1N2 influenza virus containing genes from the 2009 pandemic human H1N1 virus in swine from eastern China. *Virus Genes* 2016, 52(3): 405-410.
 110. Makoschey B, Berge AC: Review on bovine respiratory syncytial virus and bovine parainfluenza - usual suspects in bovine respiratory disease - a narrative review. *BMC Vet Res* 2021, 17(1): 261.
 111. Crowe JE: Antibody Determinants of Influenza Immunity. *J Infect Dis* 2019, 219(Suppl_1): S21-s29.
 112. Erickson N, Waldner C, Snyder E, Araya MB, Sniatynski M, Ellis J: Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus, bovine parainfluenza virus Type 3, and bovine coronavirus following neonatal mucosal priming of beef calves. *Can Vet J* 2024, 65(8): 791-801.
 113. Shi HF, Zhu YM, Dong XM, Cai H, Ma L, Wang S, Yan H, Wang XZ, Xue F: Pathogenesis of a genotype C strain of bovine parainfluenza virus type 3 infection in albino guinea pigs. *Virus Res* 2014, 188: 1-7.
 114. Sun X, Ma H, Wang X, Bao Z, Tang S, Yi C, Sun B: Broadly neutralizing antibodies to combat influenza virus infection. *Antiviral Res* 2024, 221: 105785.
 115. Sun Y, Shen Y, Zhang X, Wang Q, Liu L, Han X, Jiang B, Wang R, Sun H, Pu J, et al: A serological survey of canine H3N2, pandemic H1N1/09 and human seasonal H3N2 influenza viruses in dogs in China. *Vet Microbiol* 2014, 168(1): 193-196.
 116. Alvarez IJ, Fort M, Pasucci J, Moreno F, Gimenez H, Näslund K, Hägglund S, Zohari S, Valarcher JF: Seroprevalence of influenza D virus in bulls in Argentina. *J Vet Diagn Invest* 2020, 32(4): 585-588.
 117. Quast M, Sreenivasan C, Sexton G, Nedland H, Singrey A, Fawcett L, Miller G, Lauer D, Voss S, Pollock S, et al: Serological evidence for the presence of influenza D virus in small ruminants. *Vet Microbiol* 2015, 180(3-4): 281-285.
 118. Ducatez MF, Pelletier C, Meyer G: Influenza D virus in cattle, France, 2011-2014. *Emerg Infect Dis* 2015, 21(2): 368-371.
 119. Murakami S, Endoh M, Kobayashi T, Takenaka-Uema A, Chambers JK, Uchida K, Nishihara M, Hause B, Horimoto T: Influenza D Virus Infection in Herd of Cattle, Japan. *Emerg Infect Dis* 2016, 22(8): 1517-1519.
 120. Snoeck CJ, Oliva J, Pauly M, Losch S, Wildschutz F, Muller CP, Hübschen JM, Ducatez MF: Influenza D Virus Circulation in Cattle and Swine, Luxembourg, 2012-2016. *Emerg Infect Dis* 2018, 24(7): 1388-1389.
 121. Ferguson L, Luo K, Olivier AK, Cunningham FL, Blackmon S, Hanson-Dorr K, Sun H, Baroch J, Lutman MW, Quade B, et al: Influenza D Virus Infection in Feral Swine Populations, United States. *Emerg Infect Dis* 2018, 24(6): 1020-1028.
 122. Silveira S, Falkenberg SM, Kaplan BS, Crossley B, Ridpath JF, Bauermann FB, Fossler CP, Dargatz DA, Dassanayake RP, Vincent AL, et al: Serosurvey for Influenza D Virus Exposure in Cattle, United States, 2014-2015. *Emerg Infect Dis* 2019, 25(11): 2074-2080.
 123. Hallmann-Szełińska E, Szymański K, Łuniewska K, Kondratiuk K, Brydak LB: Hemagglutination inhibition antibody titers as a correlate of protection against influenza disease in the 2018/2019 epidemic season in Poland. *Acta Biochim Pol* 2020, 67(1): 93-98.
 124. Yu J, Wen Z, Hu W, Chen M, Zhang Y, Liu S, Wang G, Wang Z, Wang D, Zhai SL, et al: Influenza D virus infection in China, 2022-2023. *Emerg Microbes Infect* 2024, 13(1): 2343907.
 125. Murakami S, Sato R, Ishida H, Katayama M, Takenaka-Uema A, Horimoto T: Influenza D Virus of New Phylogenetic Lineage, Japan. *Emerg Infect Dis* 2020, 26(1): 168-171.
 126. Lee IW, Kim YI, Lim GJ, Kwon HI, Si YJ, Park SJ, Kim EH, Kim SM, Nguyen HD, Song MS, et al: Comparison of the virulence and transmissibility of canine H3N2 influenza viruses and characterization of their canine adaptation factors. *Emerg Microbes Infect* 2018, 7(1): 17.
 127. Haach V, Bastos APA, Gava D, da Fonseca FN, Morés MAZ, Coldebella A, Franco AC, Schaefer R: A polyvalent virosomal influenza vaccine induces broad cellular and humoral immunity in pigs. *Virol J* 2023, 20(1): 181.
 128. Wan Y, Kang G, Sreenivasan C, Daharsh L, Zhang J, Fan W, Wang D, Moriyama H, Li F, Li Q: A DNA Vaccine Expressing Consensus Hemagglutinin-Esterase Fusion Protein Protected Guinea Pigs from Infection by Two Lineages of Influenza D Virus. *J Virol* 2018, 92(11): e00110-18.

129. Sreenivasan CC, Sheng Z, Wang D, Li F: Host Range, Biology, and Species Specificity of Seven-Segmented Influenza Viruses-A Comparative Review on Influenza C and D. *Pathogens* 2021, 10(12): 1583.
130. Salem E, Cook EAJ, Lbacha HA, Oliva J, Awoume F, Aplogan GL, Hymann EC, Muloi D, Deem SL, Alali S, et al: Serologic Evidence for Influenza C and D Virus among Ruminants and Camelids, Africa, 1991-2015. *Emerg Infect Dis* 2017, 23(9): 1556-1559.
131. Laloli L, Licheri MF, Probst L, Licheri M, Gultom M, Holwerda M, V'Kovski P, Dijkman R: Time-resolved characterization of the innate immune response in the respiratory epithelium of human, porcine, and bovine during influenza virus infection. *Front Immunol* 2022, 13: 970325.
132. Feuerbaum S, Saile N, Pohlentz G, Muthing J, Schmidt H: De-O-Acetylation of mucin-derived sialic acids by recombinant NanS-p esterases of *Escherichia coli* O157:H7 strain EDL933. *Int J Med Microbiol* 2018, 308(8): 1113-1120.
133. Sreenivasan CC, Liu R, Gao R, Guo Y, Hause BM, Thomas M, Naveed A, Clement T, Rausch D, Christopher-Hennings J, et al: Influenza C and D Viruses Demonstrated a Differential Respiratory Tissue Tropism in a Comparative Pathogenesis Study in Guinea Pigs. *J Virol* 2023, 97(6): e0035623.
134. Mach N: The forecasting power of the mucin-microbiome interplay in livestock respiratory diseases. *Vet Q* 2024, 44(1): 1-18.
135. Nogales A, Aydillo T, Ávila-Pérez G, Escalera A, Chiem K, Cadagan R, DeDiego ML, Li F, García-Sastre A, Martínez-Sobrido L: Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo. *Front Microbiol* 2019, 10: 2862.
136. Morimoto R, Isegawa Y: Anti-Influenza Virus Activity of *Citrullus lanatus* var. *citroides* as a Functional Food: A Review. *Foods* 2023, 12(20): 3866.
137. Lanave G, Camero M, Coppola C, Marchi S, Cascone G, Salina F, Coltraro M, Odigie AE, Montomoli E, Chiapponi C, et al: Serological Evidence for Circulation of Influenza D Virus in the Ovine Population in Italy. *Pathogens* 2024, 13(2): 162.
138. Trombetta CM, Montomoli E, Di Bartolo I, Ostanello F, Chiapponi C, Marchi S: Detection of antibodies against influenza D virus in swine veterinarians in Italy in 2004. *J Med Virol* 2022, 94(6): 2855-2859.
139. Wan XF, Ferguson L, Oliva J, Rubrum A, Eckard L, Zhang X, Woolums AR, Lion A, Meyer G, Murakami S, et al: Limited Cross-Protection Provided by Prior Infection Contributes to High Prevalence of Influenza D Viruses in Cattle. *J Virol* 2020, 94(18): e00240-20.
140. Ferguson L, Eckard L, Epperson WB, Long LP, Smith D, Huston C, Genova S, Webby R, Wan XF: Influenza D virus infection in Mississippi beef cattle. *Virology* 2015, 486: 28-34.
141. Goecke NB, Liang Y, Otten ND, Hjulsager CK, Larsen LE: Characterization of Influenza D Virus in Danish Calves. *Viruses* 2022, 14(2): 423.
142. Masset N, Meurens F, Marie M, Lesage P, Lehébel A, Brisseau N, Assié S: Effectiveness of two intranasal vaccines for the control of bovine respiratory disease in newborn beef calves: A randomized non-inferiority multicentre field trial. *Vet J* 2020, 263: 105532.
143. Fekete E, Buret AG: The role of mucin O-glycans in microbiota dysbiosis, intestinal homeostasis, and host-pathogen interactions. *Am J Physiol Gastrointest Liver Physiol* 2023, 324(6): G452-g465.
144. Foni E, Chiapponi C, Baioni L, Zanni I, Merenda M, Rosignoli C, Kyriakis CS, Luini MV, Mandola ML, Bolzoni L, et al: Influenza D in Italy: towards a better understanding of an emerging viral infection in swine. *Sci Rep* 2017, 7(1): 11660.
145. Luo J, Ferguson L, Smith DR, Woolums AR, Epperson WB, Wan XF: Serological evidence for high prevalence of Influenza D Viruses in Cattle, Nebraska, United States, 2003-2004. *Virology* 2017, 501: 88-91.
146. Chiapponi C, Faccini S, Fusaro A, Moreno A, Prosperi A, Merenda M, Baioni L, Gabbi V, Rosignoli C, Alborali GL, et al: Detection of a New Genetic Cluster of Influenza D Virus in Italian Cattle. *Viruses* 2019, 11(12): 1110.
147. Gorin S, Fablet C, Quéguiner S, Barbier N, Paboeuf F, Hervé S, Rose N, Simon G: Assessment of Influenza D Virus in Domestic Pigs and Wild Boars in France: Apparent Limited Spread within Swine Populations Despite Serological Evidence of Breeding Sow Exposure. *Viruses* 2019, 12(1): 25.
148. Kowalczyk D, Szymański K, Cieślak K, Hallmann-Szeleńska E, Brydak LB: Circulation of Influenza Virus in the 2015/2016 Epidemic Season in Poland: Serological Evaluation of Anti-hemagglutinin Antibodies. *Adv Exp Med Biol* 2019, 1150: 77-82.
149. Junqueira DM, Tochetto C, Anderson TK, Gava D, Haach V, Cantão ME, Baker ALV, Schaefer R: Human-to-swine introductions and onward transmission of 2009 H1N1 pandemic influenza viruses in Brazil. *Front Microbiol* 2023, 14: 1243567.
150. Yu J, Li T, Wen Z, Wu S, Wang Z, Zheng J, Chen M, Chen F, Wei WK, Zhai SL, et al: Identification of D/Yama2019 Lineage-Like Influenza D Virus in Chinese Cattle. *Front Vet Sci* 2022, 9: 939456.
151. Upreti T, Yu J, Nogales A, Naveed A, Yu H, Chen X, Liu Y, Bowman AS, Martinez-Sobrido L, Parrish CR, et al: Influenza D virus utilizes both 9-O-acetylated N-acetylneuraminic and 9-O-acetylated N-glycolylneuraminic acids as functional entry receptors. *J Virol* 2024, 98(3): e0004224.
152. Liu R, Sreenivasan C, Yu H, Sheng Z, Newkirk SJ, An W, Smith DF, Chen X, Wang D, Li F: Influenza D virus diverges from its related influenza C virus in the recognition of 9-O-acetylated N-acetyl- or N-glycolyl-neuraminic acid-containing glycan receptors. *Virology* 2020, 545: 16-23.
153. Sreenivasan C, Thomas M, Sheng Z, Hause BM, Collin EA, Knudsen DE, Pillatzki A, Nelson E, Wang D, Kaushik RS, et al: Replication and Transmission of the Novel Bovine Influenza D Virus in a Guinea Pig Model. *J Virol* 2015, 89(23): 11990-12001.
154. Gaudino M, Chiapponi C, Moreno A, Zohari S, O'Donovan T, Quinless E, Sausy A, Oliva J, Salem E, Fusade-Boyer M, et al: Evolutionary and temporal dynamics of emerging influenza D virus in Europe (2009-22). *Virus Evol* 2022, 8(2): veac081.
155. Lim EH, Lim SI, Kim MJ, Kwon M, Kim MJ, Lee KB, Choe S, An DJ, Hyun BH, Park JY, et al: First Detection of Influenza D Virus Infection in Cattle and Pigs in the Republic of Korea. *Microorganisms* 2023, 11(7): 1751.
156. Kwasnik M, Rola J, Rozek W: Influenza D in Domestic and Wild Animals. *Viruses* 2023, 15(12): 2433.
157. Nedland H, Wollman J, Sreenivasan C, Quast M, Singrey A, Fawcett L, Christopher-Hennings J, Nelson E, Kaushik RS, Wang D, et al: Serological evidence for the co-circulation of two lineages of influenza D viruses in equine populations of the Midwest United States. *Zoonoses Public Health* 2018, 65(1): e148-e154.
158. Gaudino M, Moreno A, Snoeck CJ, Zohari S, Saegerman C, O'Donovan T, Ryan E, Zanni I, Foni E, Sausy A, et al: Emerging Influenza D virus infection in European livestock as determined in serology studies: Are we underestimating its spread over the continent? *Transbound Emerg Dis* 2021, 68(3): 1125-1135.
159. Salem E, Häggglund S, Cassard H, Corre T, Näslund K, Foret C, Gauthier D, Pinard A, Delverdiere M, Zohari S, et al: Pathogenesis, Host Innate Immune Response, and Aerosol Transmission of Influenza D Virus in Cattle. *J Virol* 2019, 93(7): e01853-18.

